生物制剂在炎性关节炎中的临床应用进展  

Clinical progression of biological agents on inflammatory arthritis

作　　者：王莉莎[1] 黄烽[1] 

机构地区：[1]解放军总医院风湿科,北京100853

出　　处：《中国新药杂志》2007年第15期1149-1154,共6页Chinese Journal of New Drugs

基　　金：国家自然科学基金(30571726)

摘　　要：炎性关节炎包括类风湿关节炎、强直性脊柱炎、银屑病关节炎等,是一组慢性、进展性炎性疾病,能够导致关节疼痛和功能障碍。生物治疗包括多种类型针对不同疾病发病机制的制剂。近年来,根据不同免疫和炎症机制已经研发出了多种新型的生物治疗方法。现综合国内外的文献报道和治疗进展,对近年来热点报道的生物制剂如肿瘤坏死因子阻滞剂、IL-1受体阻滞剂、IL-6受体单克隆抗体等在炎性关节炎中的应用和治疗进展进行综述,为生物制剂在风湿病中的应用提供参考。Inflammatory arthritis is comprised of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis and so on. They are a group of chronic, progressive inflammatory condition that can lead to significant disability and joint pains. Biologic therapy includes many different categories of agents targeted to diverse mechanisms of disease. Recently, a host of novel biologic therapies have been developed to attack a wide variety of immunologic and inflammatory mechanisms. This article reviewed the treatment development of biological agents, such as tumor necrosis factor blocking agents, interleukin 1 receptor antagonist and interleukin 6 receptor monoclonal antibody on inflammatory arthritis. It provides advanced therapeutic information for rheumatic diseases.

关 键 词：生物制剂 强直性脊柱炎 类风湿关节炎 银屑病关节炎 

分 类 号：R392.33[医药卫生—免疫学] R971.1[医药卫生—基础医学]